Serum adiponectin in relation to race-ethnicity and vascular risk factors in the Northern Manhattan study

Metabolic Syndrome and Related Disorders

Volumn 11, Issue 1, 2013, Pages 46-55

  Gardener, Hannah ^a   Crisby, Milita ^b   Sjoberg, Charlotte ^c   Hudson, Barry ^a   Goldberg, Ronald ^a   Mendez, Armando J ^a   Wright, Clinton B ^a   Rundek, Tatjana ^a   Elkind, Mitchell S V ^d   Sacco, Ralph L ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGE; AGED; ALCOHOL CONSUMPTION; ANTHROPOMETRY; ARTICLE; BLOOD SAMPLING; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; ETHNICITY; FEMALE; GLOMERULUS FILTRATION RATE; HISPANIC; HUMAN; HYPERTENSION; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RACE; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADIPONECTIN; AGED; BODY MASS INDEX; COHORT STUDIES; CONTINENTAL POPULATION GROUPS; CROSS-SECTIONAL STUDIES; ETHNIC GROUPS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEW YORK CITY; OBESITY; RISK FACTORS; VASCULAR DISEASES;

EID: 84872849299     PISSN: 15404196     EISSN: 15578518     Source Type: Journal    
DOI: 10.1089/met.2012.0065     Document Type: Article

References (61)

1. Im JA, Kim SH, Lee JW, et al. Association between hypoadiponectinemia and cardiovascular risk factors in nonobese healthy adults. Metabolism 2006;55:1546-1550.
2. Yamamoto Y, Hirose H, Saito I, et al. Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population. Clin Sci (Lond) 2002;103:137-142.
3. Kadowaki T, Yamauchi T, Kubota N, et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006;116:1784-1792.
4. Pischon T, Girman CJ, Hotamisligil GS, et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004 14;291:1730-1737.
5. Kumada M, Kihara S, Sumitsuji S, et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003;23:85-89.
6. Frystyk J, Berne C, Berglund L, et al. Serum adiponectin is a predictor of coronary heart disease: a population-based 10-year follow-up study in elderly men. J Clin Endocrinol Metab 2007;92:571-576.
7. Rajpathak SN, Kaplan RC, Wassertheil-Smoller S, et al. Resistin, but not adiponectin and leptin, is associated with the risk of ischemic stroke among postmenopausal women: results from the Women's Health Initiative. Stroke 2011; 42:1813-1820.
8. Matsumoto M, Ishikawa S, Kajii E. Association of adiponectin with cerebrovascular disease: A nested case-control study. Stroke 2008;39:323-328.
9. Wannamethee SG, Welsh P, Whincup PH, et al. High adiponectin and increased risk of cardiovascular disease and mortality in asymptomatic older men: Does NT-proBNP help to explain this association? Eur J Cardiovasc Prev Rehabil 2011;18:65-71.
10. Lawlor DA, Davey Smith G, Ebrahim S, et al. Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women. J Clin Endocrinol Metab 2005;90:5677-5683.
11. Lara-Castro C, Fu Y, Chung BH, et al. Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease. Curr Opin Lipidol 2007; 18:263-270.
12. Okui H, Hamasaki S, Ishida S, et al. Adiponectin is a better predictor of endothelial function of the coronary artery than HOMA-R, body mass index, immunoreactive insulin, or triglycerides. Int J Cardiol 2008;126:53-61.
13. Matsuura F, Oku H, Koseki M, et al. Adiponectin accelerates reverse cholesterol transport by increasing high density lipoprotein assembly in the liver. Biochem Biophys Res Commun 2007;358:1091-1095.
14. Oku H, Matsuura F, Koseki M, et al. Adiponectin deficiency suppresses ABCA1 expression and ApoA-I synthesis in the liver. FEBS Lett 2007;581:5029-5033.
15. Tsubakio-Yamamoto K, Matsuura F, Koseki M, et al. Adiponectin prevents atherosclerosis by increasing cholesterol efflux from macrophages. Biochem Biophys Res Commun 2008;375:390-394.
16. Weiss R, Otvos JD, Flyvbjerg A, et al. Adiponectin and lipoprotein particle size. Diabetes Care 2009;32:1317-1319.
17. Ryo M, Nakamura T, Kihara S, et al. Adiponectin as a biomarker of the metabolic syndrome. Circ J 2004;68:975-981.
18. Shand BI, Scott RS, Elder PA, et al. Plasma adiponectin in overweight, nondiabetic individuals with or without insulin resistance. Diabetes Obes Metab 2003;5:349-353.
19. Mather KJ, Funahashi T, Matsuzawa Y, et al. Adiponectin, change in adiponectin, and progression to diabetes in the Diabetes Prevention Program. Diabetes 2008;57:980-986.
20. King GA, Deemer SE, Thompson DL. Relationship between leptin, adiponectin, bone mineral density, and measures of adiposity among pre-menopausal Hispanic and Caucasian women. Endocr Res 2010;35:106-117.
21. Cohen SS, Gammon MD, Signorello LB, et al. Serum adiponectin in relation to body mass index and other correlates in black and white women. Ann Epidemiol 2011;21:86-94.
22. Sacco RL, Boden-Albala B, Abel G, et al. Race-ethnic disparities in the impact of stroke risk factors: The northern Manhattan stroke study. Stroke 2001;32:1725-1731.
23. Wallman KK, Hodgdon J. Race and ethnic standards for Federal statistics and administrative reporting. Stat Report 1977:450-454.
24. Sacco RL, Elkind M, Boden-Albala B, et al. The protective effect of moderate alcohol consumption on ischemic stroke. JAMA 1999;281:53-60.
25. Sacco RL, Gan R, Boden-Albala B, et al. Leisure-time physical activity and ischemic stroke risk: The Northern Manhattan Stroke Study. Stroke 1998;29:380-387.
26. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-3421.
27. Kargman DE, Sacco RL, Boden-Albala B, et al. Validity of telephone interview data for vascular disease risk factors in a racially mixed urban community: The Northern Manhattan Stroke Study. Neuroepidemiology 1999;18:174-184.
28. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
29. Rundek T, Gardener H, Xu Q, et al. Insulin resistance and risk of ischemic stroke among nondiabetic individuals from the northern Manhattan study. Arch Neurol 2010;67:1195-1200.
30. Bravata DM, Wells CK, Kernan WN, et al. Association between impaired insulin sensitivity and stroke. Neuroepidemiology 2005;25:69-74.
31. Schutte AE, Huisman HW, Schutte R, et al. Differences and similarities regarding adiponectin investigated in African and Caucasian women. Eur J Endocrinol 2007;157:181-188.
32. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999;257:79-83.
33. Rodriguez A, Catalan V, Gomez-Ambrosi J, et al. Visceral and subcutaneous adiposity: are both potential therapeutic targets for tackling the metabolic syndrome? Curr Pharm Des 2007;13:2169-2175.
34. Wassel CL, Pankow JS, Rasmussen-Torvik LJ, et al. Associations of SNPs in ADIPOQ and subclinical cardiovascular disease in the multi-ethnic study of atherosclerosis (MESA). Obesity (Silver Spring) 2011;19:840-847.
35. Ryu HK, Yu SY, Park JS, et al. Hypoadiponectinemia is strongly associated with metabolic syndrome in Korean type 2 diabetes patients. J Am Coll Nutr 2010;29:171-178.
36. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005;26:439-451.
37. Ohashi K, Parker JL, Ouchi N, et al. Adiponectin promotes macrophage polarization toward an anti-inflammatory phenotype. J Biol Chem 2010;285:6153-6160.
38. Isobe T, Saitoh S, Takagi S, et al. Influence of gender, age and renal function on plasma adiponectin level: the Tanno and Sobetsu study. Eur J Endocrinol 2005;153:91-98.
39. Ferris WF, Naran NH, Crowther NJ, et al. The relationship between insulin sensitivity and serum adiponectin levels in three population groups. Horm Metab Res 2005;37:695-701.
40. Fu Y, Luo N, Klein RL, et al. Adiponectin promotes adipocyte differentiation, insulin sensitivity, and lipid accumulation. J Lipid Res 2005;46:1369-1379.
41. Fantuzzi G. Adiponectin and inflammation: Consensus and controversy. J Allergy Clin Immunol 2008;121:326-330.
42. Fargnoli JL, Sun Q, Olenczuk D, et al. Resistin is associated with biomarkers of inflammation while total and highmolecular weight adiponectin are associated with biomarkers of inflammation, insulin resistance, and endothelial function. Eur J Endocrinol 2010;162:281-288.
43. Gustafson B. Adipose tissue, inflammation and atherosclerosis. J Atheroscler Thromb 2010;17:332-341.
44. Yang X, Jansson PA, Pellme F, et al. Effect of the interleukin-6 (-174) g/c promoter polymorphism on adiponectin and insulin sensitivity. Obes Res 2005;13:813-817.
45. Zhou Y, Wei Y, Wang L, et al. Decreased adiponectin and increased inflammation expression in epicardial adipose tissue in coronary artery disease. Cardiovasc Diabetol 2011;10:2.
46. DeLoach S, Huan Y, Keith SW, et al. Relationship of blood pressure and obesity with inflammatory cytokines among African Americans. Ther Adv Cardiovasc Dis 2011;5:149-157.
47. Martin LJ, Woo JG, Daniels SR, et al. The relationships of adiponectin with insulin and lipids are strengthened with increasing adiposity. J Clin Endocrinol Metab 2005;90:4255-4259.
48. Shen YY, Peake PW, Charlesworth JA. Review article: Adiponectin: Its role in kidney disease. Nephrology (Carlton) 2008;13:528-534.
49. Lin J, Hu FB, Curhan G. Serum adiponectin and renal dysfunction in men with type 2 diabetes. Diabetes Care 2007; 30:239-244.
50. Kawamoto R, Tabara Y, Kohara K, et al. Serum high molecular weight adiponectin is associated with mild renal dysfunction in Japanese adults. J Atheroscler Thromb 2010; 17:1141-1148.
51. Bang OY, Saver JL, Ovbiagele B, et al. Adiponectin levels in patients with intracranial atherosclerosis. Neurology 2007; 68:1931-1937.
52. Gardener H, Sjoberg C, Crisby M, et al. Adiponectin and carotid intima-media thickness in the Northern Manhattan Study. Stroke 2012;43:1123-1125.
53. Lo J, Dolan SE, Kanter JR, et al. Effects of obesity, body composition, and adiponectin on carotid intima-media thickness in healthy women. J Clin Endocrinol Metab 2006; 91:1677-1682.
54. Ayala C, Greenlund KJ, Croft JB, et al. Racial/ethnic disparities in mortality by stroke subtype in the United States, 1995-1998. Am J Epidemiol 2001;154:1057-1063.
55. Mensah GA, Mokdad AH, Ford ES, et al. State of disparities in cardiovascular health in the United States. Circulation 2005;111:1233-1241.
56. Sacco RL, Boden-Albala B, Gan R, et al. Stroke incidence among white, black, and Hispanic residents of an urban community: The Northern Manhattan Stroke Study. Am J Epidemiol 1998;147:259-268.
57. White H, Boden-Albala B, Wang C, et al. Ischemic stroke subtype incidence among whites, blacks, and Hispanics: The Northern Manhattan Study. Circulation 2005;111:1327-1331.
58. Kotani K, Sakane N, Saiga K, et al. Leptin: Adiponectin ratio as an atherosclerotic index in patients with type 2 diabetes: Relationship of the index to carotid intima-media thickness. Diabetologia 2005;48:2684-2686.
59. Norata GD, Raselli S, Grigore L, Garlaschelli K, Dozio E, Magni P, et al. Leptin:adiponectin ratio is an independent predictor of intima media thickness of the common carotid artery. Stroke 2007;38:2844-2846.
60. Komura N, Kihara S, Sonoda M, et al. Clinical significance of high-molecular weight form of adiponectin in male patients with coronary artery disease. Circ J 2008;72:23-28.
61. Pischon T. Use of obesity biomarkers in cardiovascular epidemiology. Dis Markers 2009;26:247-263.